Drug Information

Drug General Information
Drug ID
D0BH7Z
Former ID
DNCL002791
Drug Name
Girentuximab I-124
Synonyms
Redectane (TN)
Drug Type
Monoclonal antibody
Indication Renal cancer [ICD9: 140-229, 189; ICD10:C64] Phase 2 [522378]
Company
Wilex
Target and Pathway
Target(s) Carbonic anhydrase IX Target Info Enhancer [532138], [532748]
KEGG Pathway Nitrogen metabolism
Pathway Interaction Database HIF-1-alpha transcription factor network
Reactome Regulation of gene expression by Hypoxia-inducible Factor
Reversible hydration of carbon dioxide
WikiPathways Vitamin D Receptor Pathway
Reversible Hydration of Carbon Dioxide
Regulation of Hypoxia-inducible Factor (HIF) by Oxygen
References
Ref 522378ClinicalTrials.gov (NCT00717587) Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer. U.S. National Institutes of Health.
Ref 532138Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
Ref 532748Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab. J Nucl Med. 2014 Jun;55(6):1035-40.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.